Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Research and Patents on Coronavirus and COVID-19: A Review

Author(s): Pilar Aranda, Bernd Wicklein, Cristina Ruiz-Garcia, Raquel Martín-Sampedro, Margarita Darder, Gustavo del Real and Eduardo Ruiz-Hitzky*

Volume 14, Issue 4, 2020

Page: [328 - 350] Pages: 23

DOI: 10.2174/1872210514666201021145735

Abstract

Background: COVID-19 pandemic is a global problem that requires the point of view of basic sciences and medicine as well as social, economics and politics disciplines. Viral particles of coronaviruses including SARS-CoV-2 as well as other enveloped viruses like influenza virus could be considered as an approximation to functional core-shell nanoparticles and therefore, their study enters the realm of nanotechnology. In this context, nanotechnology can contribute to alleviate some of the current challenges posed by COVID-19 pandemic.

Methods: The present analysis contributed to diverse sources of general information, databases on scientific literature and patents to produce a review affording information on relevant areas where as nanotechnology has offered response to coronavirus challenges in the past and may be relevant now, and has offered an update of the current information on SARS-CoV-2 and COVID-19 issues.

Results: This review contribution includes specific information including: 1) An introduction to current research on nanotechnology and related recent patents for COVID-19 responses; 2) Analysis of nonimmunogenic and immunogenic prophylaxis of COVID-19 using Nanotechnology; 3) Tools devoted to detection & diagnosis of coronaviruses and COVID-19: the role of Nanotechnology; and 4) A compilation on the research and patents on nanotechnology dealing with therapeutics & treatments of COVID-19.

Conclusion: Among the increasing literature on COVID-19, there are few works analyzing the relevance of Nanotechnology, and giving an analysis on patents dealing with coronaviruses that may provide useful information on the area. This review offers a general view of the current research investigation and recent patents dealing with aspects of immunogenic and non-immunogenic prophylaxis, detection and diagnosis as well as therapeutics and treatments.

Keywords: COVID-19, SARS-CoV-2, detection, prophylaxis, diagnosis, treatment, vaccines, nanoparticles.

« Previous Next »
Graphical Abstract

[1]
Prasat PN. Introduction to Nanomedicine and Nanoengineering. Hoboken, N.J., USA: John Wiley & Sons, Inc. 2012.
[2]
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard https://covid19.who.int/?gclid=Cj0KCQjwz4z3BRCgARIsAES_OVf5xjeLwww1LmtQrCE8Cfu9tMyXB7vzdl_bVqs0J9TWcMFonhX4vQMaAumZEALw_wcB[Accessed June 2020].
[3]
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-1 2020.https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Accessed June 2020].
[4]
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20(5): 533-4.
[http://dx.doi.org/10.1016/S1473-3099(20)30120-1] [PMID: 32087114]
[5]
Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. ACS Nano 2020; 14(5): 5268-77.
[http://dx.doi.org/10.1021/acsnano.0c02439] [PMID: 32281785]
[6]
Huang H, Fan C, Li M, et al. COVID-19: A Call for physical scientists and engineers. ACS Nano 2020; 14(4): 3747-54.
[http://dx.doi.org/10.1021/acsnano.0c02618] [PMID: 32267678]
[7]
A History of Violence - How Soap Attacks a Coronavirus https://www.engineering.com/DesignerEdge/DesignerEdgeArticles/ArticleID/20146/A-History-of-ViolenceHow-Soap-Attacks-a-Coronavirus.aspx[Accessed June 2020]
[8]
The Tip of the Spear: What Does the Coronavirus Spike Really Look Like? https://www.engineering.com/Hardware/ArticleID/ 20085/The-Tip-of-the-Spear-What-Does-the-Coronavirus-Spike-Really-Look-Like.aspx?e_src=relart [Accessed June 2020].
[9]
Chan WCW. Nano research for COVID-19. ACS Nano 2020; 14(4): 3719-20.
[http://dx.doi.org/10.1021/acsnano.0c02540] [PMID: 32227916]
[10]
World Health Organization. Q&A on coronaviruses (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses[Accessed June 2020].
[11]
Lewis D. Is the coronavirus airborne? Experts can’t agree. Nature 2020; 580(7802): 175-5.
[http://dx.doi.org/10.1038/d41586-020-00974-w] [PMID: 32242113]
[12]
Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104(3): 246-51.
[http://dx.doi.org/10.1016/j.jhin.2020.01.022] [PMID: 32035997]
[13]
Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020; 5(48)eabd0110
[http://dx.doi.org/10.1126/sciimmunol.abd0110] [PMID: 32503877]
[14]
Ledford H. Coronavirus breakthrough: Dexamethasone is first drug shown to save lives. Nature 2020; 582(7813): 469.
[http://dx.doi.org/10.1038/d41586-020-01824-5] [PMID: 32546811]
[15]
Alshweiat A, Ambrus R, Csoka I. intranasal nanoparticulate systems as alternative route of drug delivery. Curr Med Chem 2019; 26(35): 6459-92.
[http://dx.doi.org/10.2174/0929867326666190827151741] [PMID: 31453778]
[16]
Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine 2014; 32(3): 327-37.
[http://dx.doi.org/10.1016/j.vaccine.2013.11.069] [PMID: 24295808]
[17]
Ruiz-Hitzky E, Darder M, Aranda P, del Burgo MÁM, del Real G. Bionanocomposites as new carriers for influenza vaccines. Adv Mater 2009; 21(41): 4167-71.
[http://dx.doi.org/10.1002/adma.200900181]
[18]
Itani R, Tobaiqy M, Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020; 10(13): 5932-42.
[http://dx.doi.org/10.7150/thno.46691] [PMID: 32483428]
[19]
Sportelli MC, Izzi M, Kukushkina EA, et al. Can nanotechnology and materials science help the fight against SARS-CoV-2? Nanomaterials (Basel) 2020; 10(4): 802.
[http://dx.doi.org/10.3390/nano10040802] [PMID: 32326343]
[20]
Ruiz-Hitzky E, Darder M, Wicklein B, et al. Nanotechnology responses to COVID-19. Adv Healthc Mater 2020; 9(19)e2000979
[http://dx.doi.org/10.1002/adhm.202000979] [PMID: 32885616]
[21]
Spanish Patent and Trademark Office. Technological Alert on “Coronavirus: diagnosis and therapy in humans” https://www. oepm.es/en/informacion_tecnologica/informacion_gratuita/Alertas_Tecnologicas/detalle.html?id=68400&n=CORONAVIRUS [Accessed June 2020].
[22]
Spanish Patent and Trademark Office.. Technological Surveillance Bulletins on “Coronavirus Diagnóstico y Terapia en Humanos” https://www.oepm.es/en/informacion_tecnologica/informacion_gratuita/boletines_de_vigilancia_tecnologica/boletines_oepm/coronavirus/index.html [Accessed June 2020].
[23]
Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6(3): 315-31.
[http://dx.doi.org/10.1021/acscentsci.0c00272]
[24]
European Patent Office. ESPACENET Patent Search https://worldwide.espacenet.com/patent/[Accessed June 2020].
[25]
Gabbay J. Antimicrobial and antiviral polymeric materials and a process for preparing the same. US2004247653A1, 2004.
[26]
Chao YC, Liu YY. Recombinant baculovirus and virus-like particle.US2005208066A1, 2004.
[27]
Lambkin-Williams R, Mann A, Oxford JS, Reip PW, Ren G.Virucidal materials. WO2007093808A2, 2007..
[28]
Marasco W, Sui J. Antibodies against SARS-CoV and methods of use thereof. WO2007044695A2, 2006..
[29]
Furuno M, Kato H, Komano A, et al. Method of solid phase extraction of toxin or virus-containing contaminated fluid, method of detoxification thereof, solid phase extraction collector and decontamination agent using the same. JP2009256297A, 2008..
[30]
Baras B, Callendret B, Escriou NRX, et al. Vaccine. CA2704283A1, 2008..
[31]
Hu K, Qiu M, Sun X, Wang J, Yang Y, Zhou L. Protein suspension chip for quantitatively detecting severe respiratory tract syndrome coronary virus and method for making same. CN101493461A,2009..
[32]
Cho CS, Han SH, Park SM, Quan JS, Shim BS, Yun CH. SARS vaccine nano-delivery system. KR Patent 101132413B1, 2009..
[33]
Chung MA, Hong HB, Kim TW, Lee SH, Sohn SW, Yoo SM. Peptide compounds for detecting or inhibiting SARS coronavirus and application thereof. US Patent 2010304363A1 2009.
[34]
Fujimori Y, Nakayama T, Sato T. Antiviral agent. US Patent 2011195108A1 2009.
[35]
Lanzavecchia A. Cross-neutralizing human monoclonal antibodies to SARS-CoV and methods of use thereof. US Patent 2011159001A1, 2011.
[36]
Breedlove JL, Grignol GE, Malchesky PS. Emulsion disinfecting, sanitizing, and cleaning compositions made with hydrophobic antimicrobial agents. WO2015026706A1, 2013..
[37]
Fukushi D, Kasamatsu S, Kusaka T, Nakano K, Sasaki A, Sato A.Antiviral material, antiviral film, antiviral fiber, and antiviral product. US10327445B2. 2014.
[38]
Salaita K, Yehl K. Particle-nucleic acid conjugates and therapeutic uses related thereto. WO2016109522A1, 2014..
[39]
Chee TS, Soon TC. Self-sanitising compositions and method for the production thereof. WO2017203299A1, 2016..
[40]
Ciaramella G, Himansu S. Respiratory virus vaccines. WO2017070626A2, 2016..
[41]
Cao Y, Gao J, Hu B, Jiang X, Tong Y. Freezing preparation method and application of bioactive substance/water-soluble drug microcapsule.CN107875984A, 2017..
[42]
Bevers S, Stefaan SD K, Tomme P. Lipid nanoparticles.WO2019141814A1,. 2018.
[43]
Bouchon A, Ciaramella G, Huang E Y-C. Nucleic acid vaccines.US2019008948A1. 2018.
[44]
Halla S, Iyer R, Zhou S. Nanoparticle formulations of STING agonists. WO2019161171A1, 2019..
[45]
King NP, Sundquist WI, Votteler JP. Engineering virus-like nanocarriers for biomolecule delivery. US2020140493A1, 2019..
[46]
Li L, Weng B. A preparation method of a novel coronary pneumonia gene therapy product. CN111172195A, 2020..
[47]
Liu X, Yang C, Chen L. Nucleic acid sequence expressing SARSCoV-2 virus antigen peptide and its application. CN110951756A, 2020..
[48]
Kim SC. COVID-19 knockout DNA CoVID-19 suitable triple knockout DNAi remedy. KR20200032050A, 2020.
[49]
Liu X, Yang C, Chen L. An adenovirus vector vaccine for preventing SARS-CoV-2 infection. CN110974950A, 2020.
[50]
Feng S, Wu Y, Zhou H, Wen K, Pan X, Wang Y, Lu Y, Xu W, Zhao J, Chen J, Chen Y, Chen L, Yan W. Colloidal gold immunochromatography for combined detection of COVID-19 antigen and antibody device and its usage. CN111024954A, 2020..
[51]
Wu F, Quan H, Qin X, Wei Z, Long L. MVSV virus vector and its virus vector vaccine, a new coronary pneumonia vaccine mediated by mVSV. CN111088283A, 2020..
[52]
Gou H, Wu Y, Ou G, Deng J, Chen Y. Nucleic acid compositions,kits and methods for detecting 2019 novel coronavirus.CN110982945A, 2020..
[53]
He F, Li Y, Yang M, Yang W, Wang X, Su H, Mo Q, Xu T, Xie S. Application of host markers for COVID-19 infection.CN111041089A, 2020..
[54]
Cai Y, Jin X, Chen P. A combination of anti-coronavirus benzyl isoquinoline alkaloid and resveratrol and application thereof.CN110960532A, 2020..
[55]
Lai MYY, Cheng PKC, Lim WWL. Survival of severe acute respiratory syndrome coronavirus. Clin Infect Dis 2005; 41(7): e67-71.
[http://dx.doi.org/10.1086/433186] [PMID: 16142653]
[56]
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382(16): 1564-7.
[http://dx.doi.org/10.1056/NEJMc2004973] [PMID: 32182409]
[57]
ScienceDirect. Fomite. https://www.sciencedirect.com/topics/ medicine-and-dentistry/fomite[Accessed June 2020]
[58]
Ren S-Y, Wang W-B, Hao Y-G, et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases 2020; 8(8): 1391-9.
[http://dx.doi.org/10.12998/wjcc.v8.i8.1391] [PMID: 32368532]
[59]
Kampf G. Potential Role of Inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents. Infect Prev Pract 2020; 2(2)100044
[http://dx.doi.org/10.1016/j.infpip.2020.100044]
[60]
van Doremalen N, Bushmaker T, Munster VJ. Stability of Middle East respiratory Syndrome Coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill 2013; 18(38): 20590.
[http://dx.doi.org/10.2807/1560-7917.ES2013.18.38.20590] [PMID: 24084338]
[61]
Chan KH, Peiris JSM, Lam SY, Poon LLM, Yuen KY, Seto WH. The effects of temperature and relative humidity on the viability of the SARS coronavirus. Adv Virol 2011; 2011734690
[http://dx.doi.org/10.1155/2011/734690] [PMID: 22312351]
[62]
Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 2020; 1(1)e10
[http://dx.doi.org/10.1016/S2666-5247(20)30003-3] [PMID: 32835322]
[63]
Duan SM, Zhao XS, Wen RF, et al. SARS Research Team. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. Biomed Environ Sci 2003; 16(3): 246-55.
[PMID: 14631830]
[64]
Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol (Berl) 2005; 194(1-2): 1-6.
[http://dx.doi.org/10.1007/s00430-004-0219-0] [PMID: 15118911]
[65]
Warnes SL, Little ZR, Keevil CW. Human coronavirus 229E remains infectious on common touch surface materials. MBio 2015; 6(6): e01697-15.
[http://dx.doi.org/10.1128/mBio.01697-15] [PMID: 26556276]
[66]
Luo J, Jang HD, Sun T, et al. Compression and aggregation-resistant particles of crumpled soft sheets. ACS Nano 2011; 5(11): 8943-9.
[http://dx.doi.org/10.1021/nn203115u] [PMID: 21995602]
[67]
The WHO has clarified that they aren’t warning people against using paper money due to coronavirus https://fullfact.org/health/ coronavirus-WHO-cash-comments/[Accessed June 2020].
[68]
Lin Z. Sterilizing Currency Detector. CN101577019A, 2009..
[69]
Kusters WMA, Willemsen P. Disinfection of banknotes or coins,using electromagnetic radiation, chemical treatment or heating. NL1023317-C2, 2003..
[70]
Korenev SA, Korenev AS. Method and apparatus for destroying microbial contamination of mail and paper currency.WO2003077957-A1, 2002.
[71]
World Health Organization. Q&A: Considerations for the cleaning and disinfection of environmental surfaces in the context of COVID-19 in non-health care settings. https://www.who.int/news-room/q-a-detail/q-a-considerations-for-the-cleaning-and-disinfection-of-environmental-surfaces-in-the-context-of-covid-19-in-non-health-care-settings [Accessed June 2020].
[72]
Mitchell A, Spencer M, Edmiston C Jr. Role of healthcare apparel and other healthcare textiles in the transmission of pathogens: A review of the literature. J Hosp Infect 2015; 90(4): 285-92.
[http://dx.doi.org/10.1016/j.jhin.2015.02.017] [PMID: 25935701]
[73]
Bhattacharjee S, Joshi R, Chughtai AA, Macintyre CR. Graphene modified multifunctional personal protective clothing. Adv Mater Interfaces 2019; 6(21)1900622
[http://dx.doi.org/10.1002/admi.201900622] [PMID: 32313805]
[74]
Bedell K, Buchaklian AH, Perlman S. Efficacy of an automated multiple emitter whole-room ultraviolet-C disinfection system against coronaviruses MHV and MERS-CoV. Infect Control Hosp Epidemiol 2016; 37(5): 598-9.
[http://dx.doi.org/10.1017/ice.2015.348] [PMID: 26818469]
[75]
Kheiri S, Liu X, Thompson M. Nanoparticles at biointerfaces: Antibacterial activity and nanotoxicology. Colloids Surf B Biointerfaces 2019; 184110550
[http://dx.doi.org/10.1016/j.colsurfb.2019.110550] [PMID: 31606698]
[76]
Matharu RK, Ciric L, Edirisinghe M. Nanocomposites: Suitable alternatives as antimicrobial agents. Nanotechnology 2018; 29(28)282001
[http://dx.doi.org/10.1088/1361-6528/aabbff] [PMID: 29620531]
[77]
Joe YH, Park DH, Hwang J. Evaluation of Ag nanoparticle coated air filter against aerosolized virus: Anti-viral efficiency with dust loading. J Hazard Mater 2016; 301: 547-53.
[http://dx.doi.org/10.1016/j.jhazmat.2015.09.017] [PMID: 26434534]
[78]
Liu G, Xiao M, Zhang X, et al. A review of air filtration technologies for sustainable and healthy building ventilation. Sustain Cities Soc 2017; 32: 375-96.
[http://dx.doi.org/10.1016/j.scs.2017.04.011]
[79]
Elias B, Bar-Yam Y. Could air filtration reduce COVID-19 severity and spread? New Engl Complex Syst Inst 2020.https://necsi.edu/could-air-filtration-reduce-covid19-severity-and-spread[Accessed June 2020]
[80]
Shimabuku QL, Ueda-Nakamura T, Bergamasco R, Fagundes-Klen MR. Chick-Watson kinetics of virus inactivation with granular activated carbon modified with silver nanoparticles and/or copper oxide. Process Saf Environ Prot 2018; 117: 33-42.
[http://dx.doi.org/10.1016/j.psep.2018.04.005]
[81]
Balagna C, Perero S, Bosco F, Mollea C, Irfan M, Ferraris M. Antipathogen nanostructured coating for air filters. Appl Surf Sci 2020; 508145283
[http://dx.doi.org/10.1016/j.apsusc.2020.145283]
[82]
Li P, Li J, Feng X, et al. Metal-organic frameworks with photocatalytic bactericidal activity for integrated air cleaning. Nat Commun 2019; 10(1): 2177.
[http://dx.doi.org/10.1038/s41467-019-10218-9] [PMID: 31097709]
[83]
Yong Z. Manufacturing method of medical protective sintered breathable material with sterilization channel. CN111117042A,2020..
[84]
Jin Y, Long J, Ma X, et al. Synthesis of caged iodine-modified zno nanomaterials and study on their visible light photocatalytic antibacterial properties. Appl Catal B 2019; 256117873.
[http://dx.doi.org/1010.1016/j.apcatb.2019.117873 [Accessed June 2020].]
[85]
Wiehe A, O’Brien JM, Senge MO. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci 2019; 18(11): 2565-612.
[http://dx.doi.org/10.1039/C9PP00211A] [PMID: 31397467]
[86]
Ojha A. Nanomaterials for removal of waterborne pathogens: Opportunities and challenges. Waterborne pathogens: Detection and treatment. butterworth-heinemann 2020; pp. 385-432.
[http://dx.doi.org/10.1016/B978-0-12-818783-8.00019-0]
[87]
Zhang C, Zhang M, Li Y, Shuai D. Visible-light-driven photocatalytic disinfection of human adenovirus by a novel heterostructure of oxygen-doped graphitic carbon nitride and hydrothermal carbonation carbon. Appl Catal B 2019; 248: 11-21.
[http://dx.doi.org/10.1016/j.apcatb.2019.02.009]
[88]
Rodríguez-González V, Obregón S, Patrón-Soberano OA, Terashima C, Fujishima A. An approach to the photocatalytic mechanism in the TiO2-nanomaterials microorganism interface for the control of infectious processes. Appl Catal B 2020; 270118853
[http://dx.doi.org/10.1016/j.apcatb.2020.118853] [PMID: 32292243]
[89]
Coronavirus: Nanotech Surface Sanitizes Milan with Nanomaterials Remaining Self-sterilized for Years . https://statnano.com// news/67531/Coronavirus-Nanotech-Surface-Sanitizes-Milan-with-Nanomaterials-Remaining-Self-sterilized-for-Years[Accessed June 2020].
[90]
Haldar J, An D, de Cienfuegos LA, Chen J, Klibanov AM. Polymeric coatings that inactivate viruses and bacteria. WO Patent 2008/127416 A2, 2006; A2..
[91]
Haldar J, An D, de Cienfuegos LA, Chen J, Klibanov AM. Polymeric coatings that inactivate viruses and bacteria. WO Patent 2006; 2008/127416: A2..
[92]
Hsu BB, Yinn Wong S, Hammond PT, Chen J, Klibanov AM. Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations. Proc Natl Acad Sci USA 2011; 108(1): 61-6.
[http://dx.doi.org/10.1073/pnas.1017012108] [PMID: 21173278]
[93]
Liu H, Elkin I, Chen J, Klibanov AM. Why do some immobilized N-alkylated polyethylenimines far surpass others in inactivating influenza viruses? Biomacromolecules 2015; 16(1): 351-6.
[http://dx.doi.org/10.1021/bm5015427] [PMID: 25486335]
[94]
Swanson M J. Virus Inactivating coatings. WO Patent 9639821A1, 1995.
[95]
Mi X, Vijayaragavan KS, Heldt CL. Virus adsorption of water-stable quaternized chitosan nanofibers. Carbohydr Res 2014; 387: 24-9.
[http://dx.doi.org/10.1016/j.carres.2014.01.017] [PMID: 24561959]
[96]
Bai B, Mi X, Xiang X, Heiden PA, Heldt CL. Non-enveloped virus reduction with quaternized chitosan nanofibers containing graphene. Carbohydr Res 2013; 380: 137-42.
[http://dx.doi.org/10.1016/j.carres.2013.08.020] [PMID: 24041631]
[97]
Beaulieu C, Blais A. Virus adsorption of water-stable quaternized chitosan nanofibers. Carbohydr Res 2007; 387: 24-9.
[98]
Castro MJL, Fabra RMJ, Cabedo ML, Sánchez MG, Lagarón CJM. Antimicrobial nanocomposites and electrospun coatings based on Poly(3-Hydroxybutyrate-Co-3-Hydroxyvalerate) and copper oxide nanoparticles for active packaging and coating applications. J Appl Polym Sci 2018; 135(2): 45673.
[http://dx.doi.org/10.1002/app.45673]
[99]
Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Vaccine adjuvants: From 1920 to 2015 and beyond. Vaccines (Basel) 2015; 3(2): 320-43.
[http://dx.doi.org/10.3390/vaccines3020320] [PMID: 26343190]
[100]
World Health Organization. Accelerating a safe and effective COVID-19 vaccine https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine[Accessed June 2020].
[101]
Pelaz B, Alexiou C, Alvarez-Puebla RA, et al. Diverse applications of nanomedicine. ACS Nano 2017; 11(3): 2313-81.
[http://dx.doi.org/10.1021/acsnano.6b06040] [PMID: 28290206]
[102]
Wicklein B, Martín del Burgo MÁ, Yuste M, et al. lipid-based bio-nanohybrids for functional stabilisation of influenza vaccines. Eur J Inorg Chem 2012; 2012(32): 5186-91.
[http://dx.doi.org/10.1002/ejic.201200579]
[103]
Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: Formulating future vaccines. J Clin Invest 2016; 126(3): 799-808.
[http://dx.doi.org/10.1172/JCI81083] [PMID: 26928033]
[104]
World Health Organization. A Coordinated Global Research Roadmap: 2019 Novel Coronavirus. Geneva 2020 [Accessed June 2020]..
[105]
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) 2019.https://clinicaltrials.gov/ct2/show/NCT04283461?term=vaccine&cond=covid-19&draw=2[Accessed June 2020].
[106]
Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults . https://clinicaltrials.gov/ct2/show/NCT04368728? term=vaccine&cond=covid-19&draw=3 [Accessed June 2020].
[107]
Curevac. About CureVac’s activities regarding an mRNA based vaccine against COVID-19 https://www.curevac.com/covid-19 [Accessed June 2020].
[108]
Imperial College London. Imperial COVID-19 Vaccine Trial https://www.imperial.ac.uk/covid-19-vaccine-trial/vaccine-science[Accessed June 2020].
[109]
Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women. ISRCTNregistry. 2020.https://doi.org/doi.org/10.1186/ISRCTN17072692 [Accessed June 2020].
[110]
LSP’s portfolio company eTheRNA launches SARS-CoV-2 mRNA vaccine program for COVID-19. https://www.lspvc.com/news/lsp-s-portfolio-company-etherna-launches-sars-cov-2-mrna-vaccine-program-for-covid-19.html[Accessed June 2020].
[111]
Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10(11): 787-96.
[http://dx.doi.org/10.1038/nri2868] [PMID: 20948547]
[112]
Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine 2012; 31(1): 58-83.
[http://dx.doi.org/10.1016/j.vaccine.2012.10.083] [PMID: 23142589]
[113]
Vragniau C, Bufton JC, Garzoni F, et al. Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display. Sci Adv 2019; 5(9)eaaw2853
[http://dx.doi.org/10.1126/sciadv.aaw2853] [PMID: 31620562]
[114]
Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 2010; 74(1): 81-94.
[http://dx.doi.org/10.1128/MMBR.00031-09]
[115]
Tan K, Li R, Huang X, Liu Q. Outer membrane vesicles: Current status and future direction of these novel vaccine adjuvants. Front Microbiol 2018; 9: 783.
[http://dx.doi.org/10.3389/fmicb.2018.00783] [PMID: 29755431]
[116]
Santiago I. Trends and innovations in biosensors for COVID-19 mass testing. ChemBioChem 2020; 21: 1-11.
[http://dx.doi.org/10.1002/cbic.202000250] [PMID: 32367615]
[117]
Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 2020; 6(5): 591-605.
[http://dx.doi.org/10.1021/acscentsci.0c00501] [PMID: 32382657]
[118]
Suo T, Liu X, Feng J, et al. ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. Emerg Microbes Infect 2020; 9(1): 1259-68.
[http://dx.doi.org/10.1080/22221751.2020.1772678] [PMID: 32438868]
[119]
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano 2020; 14(6): 7617-27.
[http://dx.doi.org/10.1021/acsnano.0c03822] [PMID: 32437124]
[120]
GenMark Responds to the SARS-CoV-2 Outbreak https://www.genmarkdx.com/solutions/panels/eplex-panels/eplex-sars-cov-2-test [Accessed June 2020].
[121]
Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020; 38(7): 870-4.
[http://dx.doi.org/10.1038/s41587-020-0513-4] [PMID: 132300245]
[122]
Kim YT, Chen Y, Choi JY, et al. Integrated microdevice of reverse transcription-polymerase chain reaction with colorimetric immunochromatographic detection for rapid gene expression analysis of influenza A H1N1 virus. Biosens Bioelectron 2012; 33(1): 88-94.
[http://dx.doi.org/10.1016/j.bios.2011.12.024] [PMID: 22265877]
[123]
Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol 2020; 30(3)e2106
[http://dx.doi.org/10.1002/rmv.2106] [PMID: 32302058]
[124]
Grant BD, Anderson CE, Williford JR, et al. SARS-CoV-2 Coronavirus Antigen-Detecting Half-Strip Lateral Flow Assay Towards the Development of Point of Care Tests Using Commercially Available Reagents. 2020.https://chemrxiv.org/ articles/preprint/A_SARS-CoV-2_Coronavirus_Antigen-Detecting_Half-Strip_ Lateral_Flow_Assay_Towards_the_Development_of_Point_of_Care_Tests_Using_Commercially_Available_Reagents/12250142/1 [Accessed June 2020].
[125]
Seo G, Lee G, Kim MJ, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano 2020; 14(4): 5135-42.
[http://dx.doi.org/10.1021/acsnano.0c02823] [PMID: 32293168]
[126]
Wicklein B, del Burgo MÁM, Yuste M, et al. Biomimetic architectures for the impedimetric discrimination of influenza virus phenotypes. Adv Funct Mater 2013; 23(2): 254-62.
[http://dx.doi.org/10.1002/adfm.201200377]
[127]
Roh C, Jo SK. Quantitative and sensitive detection of SARS coronavirus nucleocapsid protein using quantum dots-conjugated RNA aptamer on chip. J Chem Technol Biotechnol 2011; 86(12): 1475-9.
[http://dx.doi.org/10.1002/jctb.2721] [PMID: 32336860]
[128]
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020; 323(22): 2249-51.
[http://dx.doi.org/10.1001/jama.2020.8259] [PMID: 32374370]
[129]
Bundschuh C, Egger M, Wiesinger K, et al. Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma. Clin Chim Acta 2020; 509: 79-82.
[http://dx.doi.org/10.1016/j.cca.2020.05.047] [PMID: 32526218]
[130]
Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 2020; 58(8): e01243-20.
[131]
Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol 2020; 92: 2243-7.
[http://dx.doi.org/10.1002/jmv.26145] [PMID: 32510168]
[132]
de Assis RR, Jain A, Nakajima R, et al. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. bioRxiv 2020.https://www.biorxiv.org/content/10.1101/2020.04.15.043364v2[Accessed June 2020].
[133]
Vashist SK. In vitro diagnostic assays for COVID-19: Recent advances and emerging trends. Diagnostics (Basel) 2020; 10(4): 202.
[http://dx.doi.org/10.3390/diagnostics10040202] [PMID: 32260471]
[134]
Pan Y, Li X, Yang G, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 2020; 81(1): e28-32.
[http://dx.doi.org/10.1016/j.jinf.2020.03.051] [PMID: 32283141]
[135]
Shen B, Zheng Y, Zhang X, et al. Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. Am J Transl Res 2020; 12(4): 1348-54.
[PMID: 32355546]
[136]
Wang Q, Du Q, Guo B, et al. A Method to prevent SARS-CoV-2 IgM false positives in gold immunochromatography and enzyme-linked immunosorbent assays. J Clin Microbiol 2020; 58(6): e00375-20.
[http://dx.doi.org/10.1128/JCM.00375-20] [PMID: 32277023]
[137]
Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; 92: 1518-24.
[http://dx.doi.org/10.1002/jmv.25727] [PMID: 32104917]
[138]
Chen Z, Zhang Z, Zhai X, et al. Rapid and sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal Chem 2020; 92(10): 7226-31.
[http://dx.doi.org/10.1021/acs.analchem.0c00784] [PMID: 32323974]
[139]
Bhalla N, Pan Y, Yang Z, Payam AF. Opportunities and challenges for biosensors and nanoscale analytical tools for pandemics: COVID-19. ACS Nano 2020; 14(7): 7783-807.
[http://dx.doi.org/10.1021/acsnano.0c04421] [PMID: 32551559]
[140]
Feng S, Wu Y, Zhou H, Liang H, Wen K, Pan X, Wang Y, Wang Y, Lu Y, Nie J, Yuan K, Xu W, Zhao J, Zhao C, Chen J, Chen Y, Chen L, Yan W, Wei S, Huang W. Fluorescence immunochromatography device for detecting COVID-19 and its use method. CN Patent 111060691A, 2020..
[141]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[142]
Zhou Q, Li Z, Luo H, Huang Y. Application of tolfenamic acid or its pharmaceutically acceptable salt in the preparation of drugs for the prevention and/or treatment of new coronavirus inflammation. CN111184707A, 2020..
[143]
Peng L, Yang J, Liang L, Tian G, Dong R, Lang J, Lu Q. Method and device for screening new coronary pneumonia drug candidates. CN Patent 111081316A, 2020..
[144]
Biontech. Why mRNA represents a disruptive new drug class. https://biontech.de/how-we-translate/mrna-therapeutics[Accessed June 2020]
[145]
Science Direct. Lipoplex . https://www.sciencedirect.com/topics/ pharmacology-toxicology-and-pharmaceutical-science/lipoplex[Accessed June 2020].
[146]
Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis 2017; 4(4): 105-31.
[http://dx.doi.org/10.1177/2049936117713593] [PMID: 28748089]
[147]
Chen L, Liang J. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng C 2020; 112110924
[http://dx.doi.org/10.1016/j.msec.2020.110924] [PMID: 32409074]
[148]
Rai M, Deshmukh SD, Ingle AP, Gupta IR, Galdiero M, Galdiero S. Metal nanoparticles: The protective nanoshield against virus infection. Crit Rev Microbiol 2016; 42(1): 46-56.
[http://dx.doi.org/10.3109/1040841X.2013.879849] [PMID: 24754250]
[149]
te Velthuis AJW, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010; 6(11)e1001176
[http://dx.doi.org/10.1371/journal.ppat.1001176] [PMID: 21079686]
[150]
Bright KR, Sicairos-Ruelas EE, Gundy PM, Gerba CP. Assessment of the antiviral properties of zeolites containing metal ions. Food Environ Virol 2009; 1(1): 37.
[http://dx.doi.org/10.1007/s12560-008-9006-1]
[151]
Mazurkova NA, Spitsyna YE, Shikina NV, Ismagilov ZR, Zagrebel’nyi SN, Ryabchikova EI. Interaction of titanium dioxide nanoparticles with influenza virus. Nanotechnol Russ 2010; 5(5): 417-20.
[http://dx.doi.org/10.1134/S1995078010050174]
[152]
Ghaffari H, Tavakoli A, Moradi A, et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci 2019; 26(1): 70.
[http://dx.doi.org/10.1186/s12929-019-0563-4] [PMID: 31500628]
[153]
Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The role of zinc in antiviral immunity. Adv Nutr 2019; 10(4): 696-710.
[http://dx.doi.org/10.1093/advances/nmz013] [PMID: 31305906]
[154]
Skalny AV, Rink L, Ajsuvakova OP, et al. Zinc and respiratory tract infections: Perspectives for COVID19. (Review). Int J Mol Med 2020; 46(1): 17-26.
[http://dx.doi.org/10.3892/ijmm.2020.4575] [PMID: 32319538]
[155]
Du T, Liang J, Dong N, et al. Glutathione-Capped Ag2S Nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding. ACS Appl Mater Interfaces 2018; 10(5): 4369-78.
[http://dx.doi.org/10.1021/acsami.7b13811] [PMID: 29337529]
[156]
Ting D, Dong N, Fang L, et al. Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. ACS Appl Nano Mater; 2018; 1(10) 5451-9.. https://pubs.acs.org/doi/10.1021/acsanm.8b00779
[157]
Łoczechin A, Séron K, Barras A, et al. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl Mater Interfaces 2019; 11(46): 42964-74.
[http://dx.doi.org/10.1021/acsami.9b15032] [PMID: 31633330]
[158]
Ivanova VT, Ivanova MV, Spitsyn BV, et al. Interaction of nanodiamonds materials with influenza viruses. J Phys Conf Ser 2012; 345: 12019.
[http://dx.doi.org/10.1088/1742-6596/345/1/012019]
[159]
Khanal M, Vausselin T, Barras A, et al. Phenylboronic-acid-modified nanoparticles: potential antiviral therapeutics. ACS Appl Mater Interfaces 2013; 5(23): 12488-98.
[http://dx.doi.org/10.1021/am403770q] [PMID: 24180242]
[160]
Ye S, Shao K, Li Z, et al. Antiviral activity of graphene oxide: How sharp edged structure and charge matter. ACS Appl Mater Interfaces 2015; 7(38): 21571-9.
[http://dx.doi.org/10.1021/acsami.5b06876] [PMID: 26370151]
[161]
Zhou Y, Jiang X, Tong T, et al. High antiviral activity of mercaptoethane sulfonate functionalized TE/BSA nanostars against arterivirus and coronavirus. RSC Advances 2020; 10(24): 14161-9.
[162]
Liu R, Xiang D, Shang L, Sun L, Zuo Z, Li J, Li Q, Gu J, Zhao Y, Han T. Chinese medicine particles, preparation method and transdermal patch for the treatment of novel coronavirus pneumonia. CN Patent 111166861A, 2020.
[163]
Rabea EI, Badawy ME-T, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: Applications and mode of action. Biomacromolecules 2003; 4(6): 1457-65.
[http://dx.doi.org/10.1021/bm034130m] [PMID: 14606868]
[164]
Vasconcelos AA, Pomin VH. Marine carbohydrate-based compounds with medicinal properties. Mar Drugs 2018; 16(7): 233.
[http://dx.doi.org/10.3390/md16070233] [PMID: 29987239]
[165]
Schandock F, Riber CF, Röcker A, et al. Macromolecular antiviral agents against zika, ebola, sars, and other pathogenic viruses. Adv Healthc Mater 2017; 6(23)1700748
[http://dx.doi.org/10.1002/adhm.201700748] [PMID: 28945945]
[166]
Li Q, Zhao Z, Zhou D, et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 2011; 32(7): 1518-25.
[http://dx.doi.org/10.1016/j.peptides.2011.05.015] [PMID: 21620914]
[167]
Karthik R, Manigandan V, Saravanan R, Rajesh RP, Chandrika B. Structural characterization and in vitro biomedical activities of sulfated chitosan from Sepia pharaonis. Int J Biol Macromol 2016; 84: 319-28.
[http://dx.doi.org/10.1016/j.ijbiomac.2015.12.030] [PMID: 26708430]
[168]
Soria-Martinez L, Bauer S, Giesler M, et al. Prophylactic antiviral activity of sulfated glycomimetic oligomers and polymers. J Am Chem Soc 2020; 142(11): 5252-65.
[http://dx.doi.org/10.1021/jacs.9b13484] [PMID: 32105452]
[169]
Tang S, Puryear WB, Seifried BM, et al. Antiviral agents from multivalent presentation of sialyl oligosaccharides on brush polymers. ACS Macro Lett 2016; 5(3): 413-8.
[http://dx.doi.org/10.1021/acsmacrolett.5b00917]
[170]
Günther SC, Maier JD, Vetter J, et al. Antiviral potential of 3′-sialyllactose- and 6′-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses. Sci Rep 2020; 10(1): 768.
[http://dx.doi.org/10.1038/s41598-020-57608-4] [PMID: 319649432]
[171]
Karagozlu MZ, Karadeniz F, Kim S-K. Anti-HIV activities of novel synthetic peptide conjugated chitosan oligomers. Int J Biol Macromol 2014; 66: 260-6.
[http://dx.doi.org/10.1016/j.ijbiomac.2014.02.020] [PMID: 24556119]
[172]
Chun H, Yeom M, Kim H-O, et al. Efficient antiviral co-delivery using polymersomes by controlling the surface density of cell-targeting groups for influenza A virus treatment. Polym Chem 2018; 9(16): 2116-23.
[http://dx.doi.org/10.1039/C8PY00116B]
[173]
Kim H-O, Yeom M, Kim J, et al. Reactive oxygen species-regulating polymersome as an antiviral agent against influenza Virus. Small 2017; 13(32)1700818
[http://dx.doi.org/10.1002/smll.201700818] [PMID: 28692767]
[174]
Ni L, Chen Y, Chen R. An astaxanthin preparation for antiviral. CN111150722A, 2020..
[175]
Schlake T, Thran M, Fiedler K, Heidenreich R, Petsch B, Fotin-Mleczek M. mRNA: A novel avenue to antibody therapy? Mol Ther 2019; 27(4): 773-84.
[http://dx.doi.org/10.1016/j.ymthe.2019.03.002] [PMID: 30885573]
[176]
Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of Covid-19.. . https://www.neurimmune.com/news/neurimmune-andethris- sign-collaboration-agreement-to-rapidly-develop-inhaledmrna- based-antibody-therapy-for-the-treatment-of-covid-19[Accessed June 2020]
[177]
Moderna. Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-dosing-first-monoclonal-antibody-encoded-mrna/ [Accessed June 2020].
[178]
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545-8.
[http://dx.doi.org/10.1172/JCI138003] [PMID: 32167489]
[179]
Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9): 695-703.
[http://dx.doi.org/10.1038/nrmicro974] [PMID: 15372080]
[180]
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-Developing a new class of drugs. Nat Rev Drug Discov 2014; 13(10): 759-80.
[http://dx.doi.org/10.1038/nrd4278] [PMID: 25233993]
[181]
Lutz J, Lazzaro S, Habbeddine M, et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2017; 2(1): 29.
[http://dx.doi.org/10.1038/s41541-017-0032-6] [PMID: 29263884]
[182]
Sohrab SS, El-Kafrawy SA, Mirza Z, Kamal MA, Azhar EI. Design and delivery of therapeutic siRNAs: Application to MERS-Coronavirus. Curr Pharm Des 2018; 24(1): 62-77.
[http://dx.doi.org/10.2174/1381612823666171109112307] [PMID: 29119921]
[183]
Park H-J, Jeon EJ, Lee JS, et al. Galactosylated lipidoid nanoparticles for delivery of small interfering RNA to inhibit hepatitis C viral replication in vivo. Adv Healthc Mater 2016; 5(22): 2931-41.
[http://dx.doi.org/10.1002/adhm.201600416] [PMID: 27774775]
[184]
Jiang Y, Huo S, Hardie J, Liang X-J, Rotello VM. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv 2016; 13(4): 547-59.
[http://dx.doi.org/10.1517/17425247.2016.1134486] [PMID: 26735861]
[185]
Adesina SK, Akala EO. Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol Pharm 2015; 12(12): 4175-87.
[http://dx.doi.org/10.1021/acs.molpharmaceut.5b00335] [PMID: 26524196]
[186]
Zhang P, Zhang Z, Li Q, Du H, Du Y, Wang X, Hu R, Dong C. Small interfering nucleic acid for inhibiting new coronavirus and its composition and application. CN111139241A, 2020.
[187]
Zhang P, Zhang Z; Li Q, Du H, Du Y, Wang X, Hu R, Dong C. A small interfering nucleic acid and its composition and application. CN Patent 111139242A, 2020..

Rights & Permissions Print Cite
Article Metrics
43
© 2024 Bentham Science Publishers | Privacy Policy